but the results of each trial did not support its use beyond 3 hours.都是证明阿替普酶静脉溶栓...
9 RegisterLog in Sign up with one click: Facebook Twitter Google Share on Facebook (redirected fromECASS) Medical Acronyms Export Control Automated Support System Also called ECASS. A database of license information compiled and maintained by theBureau of Industry and Securityin the U.S. Departme...
溶 疗实践习惯改变极慢,对溶栓仍持怀疑的态 栓的影像评估试验 EchoplanarImaging Evaluation 度,加之溶栓时间窗的限制,导致实际溶栓率 ThrombolyticTrial,EPITHET B31 很低。在欧美,非专业中心医院的溶栓治疗率 是2008年发表的澳大利亚的研究,依据MRI 万方数据 JStroke,Jan2009,Vol4,No.I ⅢChin 所见不匹配而扩大...
Objective To determine the feasibility of a definitive trial in primary care of electronic clinical decision support (eCDS) for possible oesophago-gastric (O-G) cancer. Design and setting Feasibility study in 42 general practices in two regions of England, cluster randomised controlled trial design ...
Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-A... Thrombolysis for acute ischaemic stroke has been investigated in several clinical trials, with variable results. We have assessed the safety and...
OBJECTIVES: (1) To determine whether and how outcome measurements in the ECASS trial are influenced by a shorter time window (0-3 vs. 3-6 h) between onset of symptoms and start of thrombolytic therapy using recombinant tissue plasminogen activator (rt-PA) in acute ischemic stroke. (...
In the USA, recombinant tissue plasminogen activator (rt-PA) has been approved for therapy of acute ischemic stroke (AIS) within a 3 hour time window based on the results of the NINDS [1] trial. Only few patients with AIS are referred to a hospital within three hours after onset of ...
Objectives: (1) To determine whether and how outcome measurements in the ECASS trial are influenced by a shorter time window (0–3 vs. 3–6 h) between onset of symptoms and start of thrombolytic therapy using recombinant tissue plasminogen activator (rt-PA) in acute ischemic stroke. (2)...
We re-examined the effect of time to treatment with intravenous rt-PA (alteplase) on therapeutic benefit and clinical risk by adding recent trial data to the analysis. We added data from ECASS III (821 patients) and EPITHET (100 patients) to a pool of common data elements from six other ...
Stroke treatment with alteplase given 3·0-4·5 h after onset of acute ischemic stroke (ES III): additional outcomes and subgroup analysis of a randomized controlled trial. Lancet Neurol. 2009; 8 :1095–102.Bluhmki E, Chamorro A, Dávalos A, Machnig T, Sauce C, Wahlgren N, et al. ...